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Mesenchymal stem cells (MSCs) are promising candidates for cellular therapies due to their ability to migrate to damaged tissue
without inducing immune reaction.Many techniques have been developed to traceMSCs and their differentiation efficacy; however,
all of these methods have limitations. Conjugated polymer based water-dispersible nanoparticles (CPN) represent a new class of
probes because they offer high brightness, improved photostability, high fluorescent quantum yield, and noncytotoxicity comparing
to conventional dyes and quantumdots.We aimed to use this tool for tracingMSCs’ fate in vitro and in vivo.MSCmarker expression,
survival, and differentiation capacity were assessed uponCPN treatment. Our results showed that after CPN labeling,MSCmarkers
did not change and significant number of cells were found to be viable as revealed by MTT. Fluorescent signals were retained for 3
weeks after they were differentiated into osteocytes, adipocytes, and chondrocytes in vitro. We also showed that the labeled MSCs
migrated to the site of injury and retained their labels in an in vivo liver regeneration model. The utilization of nanoparticle could
be a promising tool for the tracking of MSCs in vivo and in vitro and therefore can be a useful tool to understand differentiation
and homing mechanisms of MSCs.
1. Introduction
Stem cells are the newhope for the century since they have the
potential to differentiate into several types of cells and tissues.
Applications involving the use of stem cells in humans that
might have been considered “science fiction” fewer than 20
years ago are nowbeing utilizedwith a great success rate [1, 2].
Described by the pioneering studies of Friedenstein et al.
[3] in 1970, mesenchymal stem cells (MSCs) are multipotent
cells, capable of self-renewal and differentiating into multi-
ple lineages, such as osteocytes, adipocytes, chondrocytes,
myoblasts, and cardiomyocytes [4–6]. MSCs have a high
potential for regenerative medicine and tissue engineering
not only due to their intrinsic self-renewal capacity and ability
to differentiate functional cell types in specific tissues but also
due to their homing capacity and nonimmunogenic features
[2, 7]. Therefore use of MSCs may provide new strategies for
many debilitating diseases including neurodegenerative and
cardiovascular diseases, diabetes, and cancer [5, 8, 9].
One of the hurdles that need to be tackled is to be sure
that transplanted stem cells are able to find the injured tissue
and function. Tracking the stem cells in vivo and in vitro
has beneficiary effects on understanding the biology of stem
cells [10]. Several labeling agents are being used for tracking
the MSCs and differentiated cells [10–12] and involve the use
of fluorescence-based detection schemes [13, 14]. Small fluo-
rescent dyes and fluorescent proteins are used as traditional
fluorescent markers but exhibit poor photostability as they
fade away rapidly during imaging [15] limiting their use in
longer-termmonitoring of live cells. Luminescent nanoparti-
cles (NPs), such as quantum dots and dye-loaded silica NPs,
appear to be more suitable for these purposes as these NPs
possess high brightness and photostability compared to small
Hindawi Publishing Corporation
BioMed Research International
Volume 2015, Article ID 298430, 9 pages
http://dx.doi.org/10.1155/2015/298430
2 BioMed Research International
fluorescent dyes [16, 17].However, their cytotoxicity is consid-
ered a serious problem for in vivo application because of the
presence of toxic heavy metals (e.g., cadmium). Dye-loaded
silica NPs also have drawbacks since only limited amount of
dyes can be loaded due to 𝜋-𝜋 interaction between the dye
molecules, which causes reduced fluorescent quantum yields
[18]. 𝜋-𝜋 interactions are noncovalent interactions in which
electron rich 𝜋 system can interact with a cationic or neutral
metal, an anion, or another 𝜋 system from another molecule.
This type of noncovalent interactions involving 𝜋 systems is
known to have a paramount role in biological events such as
protein-ligand recognition [19].
A largely unexplored alternative is the use of functional-
conjugated polymer particles as fluorescent labels. Recently
NPs based on conjugated polymers (CPN) are emerging as
a new class of luminescent NPs [20]. These NPs have many
potential applications, including imaging agents, biosensors,
and optoelectronic devices, because of their high quantum
yields, molar absorptivity, photostability, and easy synthesis
[21, 22].
We aim to demonstrate the use of self-fluorescence CPN
as a biocompatible photostable fluorescent label in order to
follow the fate of MSCs in vitro and in vivo.
2. Material and Methods
2.1. Isolation and Culture of MSCs. TheMSCs were obtained
from three 6-month-old Sprague-Dawley female rats. After
cervical dislocation, bone marrow heterogeneous cell popu-
lation was obtained from femur and tibia by flushing DMEM
(Dulbecco’s modified Eagle’s medium, Invitrogen, Paisley,
UK) containing 10% FBS (fetal bovine serum, HyClone,
Logan, UT, USA).The isolatedMSCs were cultured in plastic
culture dishes with MesenCult Media (StemCell Technol-
ogy, Vancouver, Canada) including 20% supplement (Stem-
Cell Technology) and a 1% penicillin/streptomycin solution
(HyClone). The cells were cultured in a 5% CO
2
incubator at
37∘C. The medium of cells was changed twice a week for 14
days.
2.2. Labeling MSCs with Conjugated Polymer Nanoparticles
(CPNs). CPNs were prepared at the Department of Chem-
istry at Bilkent University. The copolymer was synthesized
using the Suzuki coupling polymerization technique and
after the synthesis of polymers they were converted into
nanoparticles by reprecipitationmethod as shown previously
[22]. Media of MSCs on 13th day were changed with media
including CPNs in 1 : 4 ratio (25𝜇g/mL) ofMesenCult media.
MSCs were checked under fluorescence microscopy with
fluorescein isothiocyanate (FITC) filter. 494 nm is the max-
excitation and 519 nm is the max-emission of FITC. ImageJ
analysis was performed to count CPN-MSCs in the slides.
2.3. Total RNA Isolation, RT-PCR. In order to assess the effect
of CPN labeling in the expression of the markers of MSCs,
we investigated their expression at day 14 of the culture.
CulturedCPN treated and nontreatedMSCswere trypsinized
and total RNAs were isolated with the RNeasy Mini kit Stem
Cell Rev and Rep (Qiagen, Hilden, Germany) according to
the manufacturer’s protocol. The cDNAs were synthesized
from total RNA with the DyNAmo cDNA synthesis kit
(Finnzymes, Espoo, Finland) according to themanufacturer’s
protocol. These cDNAs were used for MSCs marker analysis
with PCR. Primers and PCR conditions used for cDNA
amplification were listed in Tables 1 and 2.
2.4. MTT Assay for Cellular Metabolic Activity. The
viability of CPN treated MSCs was detected via 3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide
(MTT) assay (Roche Molecular Biochemicals, Indianapolis,
USA). 104 MSCs were cultured in the wells of 96-well plates.
Three sets of MSCs isolated from 6-month-old rat bone
marrow samples were treated with MesenCult medium
with CPNs and three sets were cultured only in MesenCult
medium for 24 hours, at which time the MTT reagent was
applied at a final concentration of 0.5mg/mL for 4 hours
at 37∘C in a 5% CO
2
incubator. The absorbance of the end
product formazan was measured with ELISA reader (BioTek,
KCJrWin software) at a primary wavelength of 551 nm and a
maximum wavelength of 601 nm.The numeric values for the
MTT assays were listed in Table 3.
2.5. Lactate Dehydrogenase (LDH) Assay for Cellular Toxicity.
2 × 104 MSCs were placed in 96-well plates in triplicate.
CPN was added to the MSC culture media in 1 : 4 ratio
(25 𝜇g/mL). Since 1% Triton-X is known to be toxic for cells,
it was used as a positive control for LDH activity (high
control) and hence maximum toxicity. We also used another
control group (low control) in which MSCs were not labeled
with CPN and incubated in the medium without Triton-
X. This provided data for the minimum toxicity. After 24 h
incubation, the toxicity ofCPNwas determined bymeasuring
the release of cytoplasmic LDH from the damaged cells with
Cytotoxicity Detection Kit (LDH, Clontech) according to
manufacturer’s protocol. The readings were performed by
using an ELISA reader (BioTek, KCJrWin software) at the
wavelength value of 490 nm. For the calculations, the average
value of background group readings was subtracted from all
of the sample readings. The percent cytotoxicity value was
calculated by the following equation:
Cytotoxicity (%)
=
(Triplicate Absorbance − Low Control)
(High Control − Low Control)
∗ 100.
(1)
The numeric values for the LDH assays were listed in Table 4.
2.6. Osteogenic Differentiation of CPN-Labelled MSCs and
Alizarin Red Staining. On the 13th day of culture when
MSCs reached 80%confluency,CPNwas added toMesenCult
media in 1 : 4 ratio (25𝜇g/mL). After MSCs were incubated
with CPN for 24 h, themediumwas changedwith freshly pre-
pared osteogenic differentiation medium containing 0.1 𝜇M
dexamethasone (Sigma), 0.2mM ascorbic acid 2-phosphate
(Sigma), and 10mM glycerol-2-phosphate (Sigma) to LG-
DMEM (low glucose Dulbecco’s modified Eagle’s medium)
(HyClone), 1x penicillin-streptomycin (HyClone), and 10%
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Table 1: RT-PCR conditions for each primer.
Beta-actin Forward
Reverse
5󸀠-CTGGCCTCACTGTCCACCTT-3󸀠
5󸀠-GGGCCGGACTCATCGTACT-3󸀠
65 bp
CD90 Forward
Reverse
5󸀠-CCAGTCATCAGCATCACTCT-3󸀠
5󸀠-AGCTTGTCTCTGATCACATT-3󸀠
374 bp
CD34 Forward
Reverse
5󸀠-TGTCTGCTCCTTGAATCT-3󸀠
5󸀠-CCTGTGGGACTCCAACT-3󸀠
281 bp
CD71 Forward
Reverse
5󸀠-ATGGTTCGTACAGCAGCAGA-3󸀠
5󸀠-CGAGCAGAATACAGCCATTG-3󸀠
182 bp
CD29 Forward
Reverse
5󸀠-ACTTCAGACTTCCGCATTGG-3󸀠
5󸀠-GCTGCTGACCAACAAGTTCA-3󸀠
190 bp
CD45 Forward
Reverse
5󸀠-ATGTTATTGGGAGGGTGCAA-3󸀠
5󸀠-AAAATGTAACGCGCTTCAGG-3󸀠
175 bp
Table 2: RT-PCR conditions for each primer.
Genes Initial denaturation Denaturation Annealing Extension Cycle Final extension
Beta-actin 95∘C, 5min 94∘C 40 sec 60∘C 35 sec 72∘C 40 sec 25 72∘C, 5min
CD90 95∘C, 5min 94∘C 30 sec 55∘C 30 sec 72∘C 30 sec 30 72∘C, 5min
CD34 95∘C, 5min 94∘C 30 sec 55∘C 30 sec 72∘C 30 sec 30 72∘C, 5min
CD71 95∘C, 5min 94∘C 40 sec 66∘C 60 sec 72∘C 40 sec 35 72∘C, 5min
CD29 95∘C, 5min 94∘C 30 sec 60∘C 30 sec 72∘C 30 sec 29 72∘C, 5min
CD45 95∘C, 5min 94∘C 30 sec 60∘C 30 sec 72∘C 30 sec 23 72∘C, 5min
Table 3: The raw data for MTT assay.
MSC % CPN-MSC %
Sample 1 97.95 71.46
Sample 2 101.03 59.14
Sample 3 101.03 73.92
Standard deviation (SD) 1.78 7.92
FBS (HyClone). Cells were cultured for 21 days in a 5%
CO
2
incubator at 37∘C. The MSCs were not further treated
with CPN during differentiation. To assess the effect of
CPN on osteogenic differentiation, cells were fixed with 10%
formaldehyde for 15 minutes and were stained with Alizarin
Red (Sigma) for 20 minutes to detect the presence of calcium
node formation [9]. Then the cells were examined under
bright-field microscopy. For CPN detection, same sections
were examined under fluorescence microscope with FITC
filter. For the evaluation, we used an excitation wavelength
in the range of 450–500 nm and detection in the range of
515–565 nm. For counter staining to visualize nuclei, the
specimens were mounted using UltraCruz (Santa Cruz)
mounting medium with DAPI.
2.7. Adipogenic Differentiation of NP-Labelled MSCs and Oil
Red O Staining. On the 13th day of culture when MSCs
reached 80% confluency, CPN was added to MesenCult
media in 1 : 4 ratio (25 𝜇g/mL). After MSCs were incubated
with CPN for 24 h, the medium was changed with freshly
prepared adipogenic differentiationmedia consisting of 1 𝜇M
dexamethasone (Sigma), 10 𝜇g/mL insulin (Sigma), 100 𝜇M
Table 4: The raw data for LDH assay.
High control
%
Low control
(MSC) % MSC-CPN %
Sample 1 94.08 10.79 4.45
Sample 2 100.22 5.90 6.29
Sample 3 105.71 8.18 5.98
Standard deviation
(SD) 5.82 2.45 0.99
indomethacin (Sigma), and 0.5mM IBMX (isobutylmethylx-
anthine) (Sigma) to LG-DMEM (HyClone), 1x penicillin-
streptomycin (HyClone), and 10% FBS (HyClone). Cells were
cultured for 21 days in a 5%CO
2
incubator at 37∘C.TheMSCs
were not further treated with CPN during differentiation. To
assess the effect of CPN on adipogenic differentiation, cells
were fixed with 4% paraformaldehyde and (Sigma) Oil Red
O (Sigma) staining was used for detection of accumulated
oil droplets [9]. The cells were then examined under bright-
field microscopy. For CPN detection, the same sections were
examined under fluorescence microscopy with FITC filter.
For the evaluation, we used an excitation wavelength in the
range of 450–500 nm and detection in the range of 515–
565 nm. For counter staining to visualize nuclei, the speci-
mens were mounted using UltraCruz (Santa Cruz) mounting
medium with DAPI.
2.8. Chondrogenic Differentiation of NP-Labelled MSCs and
Alcian Blue Staining. On the 13th day of culture when MSCs
reached 80% confluency, CPN was added to MesenCult
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media in 1 : 4 ratio (25 𝜇g/mL). After MSCs were incubated
with CPN for 24 h, MSCs were centrifuged for 5min at
1500 rpm in round bottom tubes to form cell spheres.The cell
spheres were induced via specific chondrogenesis induction
medium composed of 10 ng/mL TGF𝛽 (transforming growth
factor beta) 1, 100 nM dexamethasone, 50 𝜇g/mL ascorbic
acid, 1mM sodium pyruvate, 6.25𝜇g/mL insulin, 6.25𝜇g/mL
transferrin, 6.25𝜇g/mL selenous acid (ITS), and 1.25mg/mL
bovine serum albumin. Cell spheres were cultured for 28
days in a 5% CO
2
incubator at 37∘C. The MSCs were not
further treated with CPN during differentiation. To assess
the effect of CPN on chondrogenic differentiation, the cell
nodules were fixed with M1 Embedding Matrix (Thermo)
and Alcian Blue (Sigma) was used to detect the presence of
cartilage condensations [23]. The cells were then examined
under bright-field microscopy. For CPN detection, the same
sections were examined under fluorescence microscopy
with FITC filter. For the evaluation, we used an excitation
wavelength in the range of 450–500 nm and detection in the
range of 515–565 nm. For counter staining to visualize nuclei,
the specimens were mounted using UltraCruz (Santa Cruz)
mounting medium with DAPI.
2.9. In Vivo Tracking of NP-Labelled MSCs. Liver injury
was generated by partial hepatectomy (PH) in 6-month-old
Sprague Dawley rats. 70% of the liver mass was resected,
and in the Sham (SH) group identical surgical procedures
were performed without resection [24]. Three animals per
group were used in the experiments. 106 MSCs (nonlabeled)
or CPN-MSCs in sterile 1x PBS were injected to the PH and
SH group of animals through their tail vein. After 3 days of
injection, the animals were sacrificed and their livers were
removed and embedded into paraffin. 5 𝜇m thick paraffin
embedded liver tissue sections were transferred to the slides.
Slides were thenmounted with UltraCruzmountingmedium
with DAPI (Santa Cruz Biotechnologies, CA, USA) for
counter staining. Slides were observed with a fluorescent
microscope (Leica TCS/SP5, Japan). Excitation wavelength
for CPN andDAPI was at 490 nm and at 359 nm, respectively.
ImageJ analysis was performed to count CPN-MSCs in the
sections.
2.10. Statistical Analysis. All data are expressed as mean ±
SD (standard deviation). Data were analyzed by performing
paired 𝑡-test usingMinitab Statistical Software (State College,
PA, USA). A value of 𝑃 < 0.05 was considered to be statis-
tically significant.
3. Results
The present study was undertaken to test whether self-fluo-
rescence nanoparticles are a valuable tool to label MSCs
without affecting their marker expression, viability, and
homing capacities. To accomplish this task bone marrow-
derived MSCs were isolated, expanded, and labeled with
fluorescent nanoparticles. The effect of labeling process on
the marker expression, viability, differentiation and homing
functions of MSCs were determined.
In order to check whether CPN labeling has any effect on
MSCs, we investigated the gene expression profiles which are
characteristics of MSCs upon CPN treatment and compared
to that of MSCs without CPN labelling. We investigated not
only the presence of MSC markers but also the absence
of hematopoietic stem cell markers. By using RT-PCR, we
showed that CPN treated MSCs were positive for MSCs
markers such as CD29, CD71, and CD90 and negative for
hematopoietic stem cell markers such as CD34 and CD45
(Figure 1(a), left panel). The pattern of expression was the
same as that of MSCs without CPN treatment (Figure 1(a),
right panel). We then investigated the efficiency of CPN
labeling in MSCs; our data showed that 70% of the MSCs
were diffusely stained after CPN labelingmeasured by ImageJ
analysis (Figure 1(b)).
To assess the effect of CNPs on the viability of MSCs,
we performed MTT assay. CNP-labeled MSCs retained 70%
of nonlabeled control MSCs’ MTT activity (Figure 2(a)). To
test whether CPNs are toxic to MSCs, we performed LDH
test (Figure 2(b)). It is important to note that two different
controls are being used in this test. The first one is the high
control where 1% Triton-X is added to the culture media
to provide maximum toxicity. The second one is the low
control, where no Triton-X is added, and this data provides
the value for minimum toxicity. By using the formula that
was given inMaterial andMethods section, the rate of toxicity
could be calculated. Our results showed that the cytotoxicity
percentage of CPN-MSC was very similar to the low control
and significantly different from the high control (∗𝑃 < 0.005)
suggesting that CPN to labelling is not toxic forMSCs (Figure
2(b)).
To evaluate whether CPN-labeled MSCs retain fluores-
cein signal after in vitro differentiation and could be used
for tracking, we induced in vitro differentiation of MSCs into
osteocytes, adipocytes, and chondrocytes after being treated
with CPNs for 24 h. MSCs were cultured in osteogenic, adi-
pogenic, and chondrogenic differentiation medium without
any furtherCPN treatment (Figure 3).Our results showed the
presence of fluorescence staining after 3 weeks for osteogenic
and adipogenic differentiation (Figures 3(b) and 3(d)) and
after 4 weeks for chondrogenic differentiation (Figure 3(f)).
These signals were colocalized with calcium node forma-
tion shown by Alizarin Red staining (Figure 3(a)), with oil
droplets shown by Oil Red O staining (Figure 3(c)), and
with cartilage condensations shown by Alcian Blue staining
(Figure 3(e)) under bright-field microscopy. CPN labeling
intensity did not fade out after MSCs were differentiated.
To validate the use of CPN-MSCs, we used a widely
accepted model of liver injury model. Rats underwent either
partial hepatectomy (PH) operation to induce injury (Figures
4(a)–4(c) and 4(g)–4(i)) or Sham (SH) operation for con-
trol (Figures 4(d)–4(f)). Then these animals were injected
either with CNP-MSCs (Figures 4(a)–4(f)) or nonlabeled
MSCs (Figures 4(g)–4(i)) from tail vein. Three days after
the injection, the rats were sacrificed and their livers were
sectioned and analyzed with fluorescence microscopy. Our
results showed that several CPN-MSCs were present when
these cells were injected after PH (Figures 4(a)–4(c)). ImageJ
analysis revealed that 8% of the cells in the section were CPN
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Figure 1: Characterization and labelling efficiency of 24 h CPN treated and nontreated MSCs. (a) After CPN-labeling MSCs (left panel) were
positive for mesenchymal stem cell markers (CD90, CD29, and CD71) and negative for hematopoietic stem cell markers (CD34 and CD45)
same as nontreated MSCs (right panel). 𝛽-Actin was used for loading control. (b) CPN-MSCs were visualized by fluorescence microscopy by
using FITC filters. DAPI staining was performed to visualize cellular DNA. Magnification bar: 100 𝜇m.
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Figure 2: Effects of 24 h CPN labeling on MSCs’ (a) cellular metabolic activity shown by MTT assay and (b) cellular toxicity shown by LDH
assay (∗𝑃 < 0.005).
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Bright field
(a)
FITC
(b)
(c) (d)
(e) (f)
Figure 3: Differentiation of CPN-labeled MSCs into ((a), (b)) osteogenic lineage, ((c), (d)) adipogenic lineage, and ((e), (f)) chondrogenic
lineage after culturing with induction medium. (a) Visualization of osteogenic lineage by Alizarin Red staining; (c) adipogenic lineage by Oil
Red O staining; and (e) chondrogenic lineage by Alcian Blue staining under bright-field microscopy. ((b), (d), and (f)) Visualization of CPN
labeling shown by using FITC filters since CPN had a similar emission and excitation wavelength to FITC. Red arrows denote some of the
positive staining for the presence of CPNs after differentiation. Magnification bar: 20 𝜇m.
labelled. No staining was observed in the liver sections after
CPN-labeledMSCs were injected to SH group (Figures 4(d)–
4(f)) or when nonlabeled MSCs were injected to PH group
(Figures 4(g)–4(i)) as expected.
4. Discussion
MSCs have a high potential for regenerative medicine and
tissue engineering not only due to their intrinsic self-renewal
capacity and ability to differentiate functional cell types in
specific tissues but also due to their homing capacity and
nonimmunogenic features [1, 2, 7]. SinceMSCs are important
tools for cell-based therapies [25–27] and nanoparticles are
promising labeling tools in noninvasive cell tracking [28],
complete assessment of CPNs on stem cells should be per-
formed.
First of all, the labeling material should be safe and not
toxic as well as easy to use. It was reported that use of
nanoparticles may cause cytotoxic effect on the cell [10] and
this has to be evaluated and this evaluation may not be very
BioMed Research International 7
FITC
(a)
DAPI
(b)
MERGE
(c)
(d) (e) (f)
(g) (h) (i)
Figure 4: In vivo tracking of CPN-MSCs. Paraffin embedded liver tissues obtained from rats that were injected with either CPN-labeled
((a)–(f)) or nonlabeled MSCs ((g)–(i)) from tail vein followed by PH ((a)–(c) and (g)–(i)) and SH ((d)–(f)). White arrows denote injected
CPN-labelled MSCs under FITC filter. Magnification bar: 10𝜇m.
straightforward [29]. This assessment should be performed
individually for each nanoparticle and cell type. We used
MTT and LDH assay as reliable quantitative methods to
assess the effect of CPNs on rat bone marrow-derived MSCs,
since these assays have been demonstrated as sensitive,
precise, convenient, rapid, and economical test method by
many studies for the measurement of in vitro cytotoxicity,
cell adhesion, cell proliferation, and cell number [30, 31]. It
has been shown that at the MTT results if the cell viability is
less than 40%, the tested material would be toxic and should
be further investigated with other methods [32]. When we
performed cytotoxicity testing 24 hours after CPN labelling,
the MTT survival rate was 70% for the CPN-labeled cells and
therefore should not be considered as toxic. In addition, LDH
assay revealed that CPN treated MSCs behaved very similar
to that of MSCs alone (low control), further suggesting
the safety of CPN labeling. In addition, CPN’s absorbance and
emission characteristics were similar to FITC which could
easily be monitored.
Other than cytotoxicity, labeling agent’s effect on the
markers of MSCs is also an important point. Therefore,
the expression profiles of CD90, CD71, CD29, CD34, and
CD45were tested to identify whether CPN treatment affected
the characteristics of MSCs. As shown previously by us
and others, these markers are widely used to characterize
MSCs [4, 8, 9]. CPN-labeled MSCs expressed CD90, CD71,
and CD29 but not CD34 or CD45, suggesting that CPN
labeling did not affect these cells’ characteristics. In addition
incubation of MSCs with CPN for 24 h resulted in stably
labeled MSCs with diffuse cytoplasmic staining.
The retaining of the label during the stem cell differentia-
tion is also a critical issue.This is especially important inMSC
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biology because current in vitro regimen for differentiation
takes three weeks for osteogenic and adipogenic differentia-
tion and four weeks for chondrogenic differentiation. When
CPN-MSCs were cultured in osteogenic, adipogenic, and
chondrogenic differentiation medium for three to four weeks
without any further CPN addition, they differentiated with
their fluorescent labels intact.There was no effect of nanopar-
ticles on the osteogenic, adipogenic, and chondrogenic differ-
entiation ability of mesenchymal stem cells since CPN-MSCs
showed the characteristic stainings of osteogenic, adipogenic,
and chondrogenic lineages by Alizarin Red, Oil Red O, and
Alcian Blue, respectively. These stainings have been used to
assess the differentiation for non-labelled, control MSCs by
us and others [9, 23].
To be able to track cells in vivo is critical to better
understand the biology during their migration and function.
A great deal of attention has been given to understand what
regulates MSCs’ migration to an injury site. However, track-
ing cells within animal’s body is a compulsive process. Many
attempts to track and monitor stem cells and cancer cells in
vivo (such as by quantum dot labeling, SPOI labeling, and
MRI detection) are challenged by cellular toxicity caused by
these materials, inadequate duration of labeling, and altera-
tion of gene expression or cellular functions [33–35]. Promis-
ingly, our results showed that CPN labeling provides an
opportunity to track MSCs in vivo safely, since labeled MSCs
migrated to injured liver and resided there without losing
their labels. However, whether these CPN-MSCs differentiate
in the injured liver is a valid question and further experiments
to test this are being planned. It is also important to note
the possibility of label dilution following MSC proliferation
longer-term in vitro and potentially in vivo, as it could
contribute to the rate of detection of fluorescent cells on liver
sections.
5. Conclusion
Wereport a new and safeway to track stem cells in vitro and in
vivo. CPN labeling might be a potential tool for the tracking
of MSCs and therefore can be used to better understand
MSCs’ differentiation and homing mechanisms without any
manipulations performed at the DNA level such as GFP or
luciferase labeling.
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